Next Phase Newsletter

A professional investment institution was founded in 2016 and headquartered in Shanghai, China. Through its fund management entity, the group invests in early- and growth-stage companies within the biomedicine sector. The firm currently manages a fund of approximately RMB ¥100 million, making equity investments typically ranging from ¥5 million to ¥20 million in Angel through Series B rounds. It is actively seeking opportunities in China, the United States, and Canada. 

The firm focuses on medicine, medical devices, diagnostics, biotechnology, and healthcare services. It seeks products with strong market potential in China that have already achieved prototype development and clinical proof-of-concept. The firm maintains an indication-agnostic approach, evaluating opportunities based on innovation and scalability rather than specific therapeutic areas. 

The firm looks for capable management teams leading companies with validated assets. It can support portfolio companies by facilitating registration and distribution partnerships in China and may request regional rights depending on the structure of the collaboration. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

 The firm is an early-stage life sciences focused venture capital investor. The firm targets Series A investment rounds but considers later stage investments and plans to make follow-on commitments throughout a company’s life cycle. Typical initial check sizes can range from $1M to $2.5M. The firm may lead or co-invest on a case-by-case basis and often syndicates with other strong life science investors. The firm invests across the United States, with a focus on underserved or underrepresented regions. 
 
The firm is interested in medical devices, diagnostics, digital health, and medical instruments. The firm does not invest in traditional drug assets but may consider peripheral areas such as drug delivery or platform technologies. For medical devices, the firm primarily considers products with B2B models and a clear FDA regulatory pathway. The firm is opportunistic in terms of indications/disease areas. For development stage, the firm prefers companies with products or assets that are within 18 months of commercialization and have a well-defined regulatory pathway. 
 

There is no specific requirement for companies and the management team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

 An impact venture investor focuses on healthcare and climate, with specialized teams for each vertical. With its current fund, the firm is allocating €1M for initial checks with flexibility to make follow-on investments. The firm invests in Seed rounds but can enter earlier or later. The firm’s investments are focused in Europe.  
 

In healthcare, the firm is technology agnostic and invests in solutions that help improve the quality of life for vulnerable populations: the elderly, people with chronic diseases, and people with mental or physical disabilities. For digital health companies, the firm seeks to see product-market fit. 

The firm can act as a lead investor and join syndicates. The firm requests to take a board seat, as it prefers to be an active investor. The firm would like to see committed and diverse management teams. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A life sciences-focused venture capital investor based in the US is actively seeking new investment opportunities. In addition, the firm recently closed on a new fund through its specialized funds business unit that invests in companies in Asia. The firm generally supports companies with lead assets that can reach high-value inflection points in 3–4 years and will consider opportunities in the U.S., Canada, Europe, Singapore, Hong Kong, and China. 

The firm is currently seeking companies developing therapeutics or medical technologies to treat true unmet medical needs. It is therapeutic area agnostic, though it has historically been most active in immunology, oncology, and rare diseases. The firm typically prefers to invest in Series A/B rounds with a preference for lead assets between 18 months pre-IND and Phase 2a. Within devices, the firm generally prefers later-stage opportunities, particularly those that have received market approval with early revenue. 

The firm does not have any specific requirements for management teams. It is an active investor and seeks a director or observer position on portfolio company boards. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

 A single-family office with U.S.-based family interests. While the firm is very flexible in terms of investment size, it generally looks to invest a minimum of $0.5M per round, depending on the round size and estimated capital call. The firm prefers Series A and later-stage companies, with Pre-A interest depending on technology stage. Currently, the firm invests only in companies based in North America.  

The firm is looking for breakthrough technologies with a strong social ethos in the therapeutics, medical devices, and diagnostics sectors that address underserved medical needs or provide innovative and disruptive approaches to common medical procedures and treatments. Areas of particular interest include optical or sound-based technologies, devices that supplant drug use, orthopedics, gene/nucleic acid-based therapies, immuno-oncology, and therapies correcting or treating loss of senses. 

The firm is currently reviewing co-investment opportunities in private companies and, on an opportunistic basis, considering investments in micro- and small-cap public companies as a direct investor. The firm prefers companies that have already raised seed financing and have received allowance of claims by the USPTO. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

 A China-based private equity firm affiliated with a global investment group has raised multiple funds to date and invests across multiple sectors, including healthcare. The firm is a full-spectrum investor, participating from Series A through pre-IPO and PIPE, and may also consider buyouts and add-on acquisitions for its portfolio. Typical investments range from $5-50M, with the capacity to commit up to $100M per company. While the firm is primarily focused on opportunities in China, it also invests in companies from the US and Europe that present a strong China angle. 

The firm invests opportunistically in the healthcare sector on a case-by-case basis. Areas of interest include biopharma, medical devices and equipment, diagnostics, healthcare IT, and R&D services with significant market potential. The firm is stage-agnostic and will consider products ranging from pre-clinical through market-approved. 

The firm invests in both private and public companies, targeting Chinese businesses as well as US- and Europe-based companies with strategic ties to the China market. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A corporate venture capital arm of a global science-based company invests in seed and venture stage companies, generally taking less than 25% ownership. While the firm has previously invested from seed through PIPE, the focus is on companies with products in development or early commercialization. Initial allocations typically range from a few hundred thousand dollars up to $5 million, with additional reserves for follow-on rounds. The firm is targeting approximately 5–10 investments in the next 6–9 months, and over 10 additional investments in the next 2 years. The investment scope is global, with a focus on the U.S., Europe, and Israel.

Within biomedical, the firm seeks materials science companies in orthopedics and soft tissue repair. In addition, the firm actively invests in human nutritional health, with a specific emphasis on personalized nutrition and companies developing nutritional products. This includes start-ups with digital or technology-driven models that enable personalization and precision.

The firm values experienced management teams and typically seeks a board seat, aiming to play an active role in portfolio companies. Strategic alignment with the parent company’s businesses is also an important consideration for investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology